The European Commission (EC) has approved Takeda’s Fruzaqla (fruquintinib) as a monotherapy for adults with metastatic colorectal cancer who have exhausted currently available standard therapies. This approval is for patients who have advanced on or are not tolerant to treatments including trifluridine-tipiracil and regorafenib. The gold standard of business intelligence.
In April 2024, the treatment received a positive opinion from the Committee for Medicinal Products for Human Use. The latest development comes after the US Food and Drug Administration (FDA) . The approval is based on data from the Phase III multi-regional FRESCO-2 trial assessing Fruzaqla along with best supportive care (BSC) versus placebo plus BSC.
The trial met all primary and key secondary efficacy endpoints with the treatment demonstrating benefit regardless of patients’ previous therapy types. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form The oral inhibitor had a manageable safety profile with adverse reactions that led to discontinuation of treatment.
Takeda holds the sole global licence for developing, marketing and manufacturing fruquintinib outside main.
